Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Colorcon
Medtronic
AstraZeneca
Dow

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VIEKIRA XR

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for VIEKIRA XR

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02461745 Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs Active, not recruiting AbbVie Phase 4 2015-06-01 This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older, with VIEKIRA PAK (ombitasvir, paritaprevir/r, dasubuvir), with or without ribavirin.
NCT02461745 Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs Active, not recruiting Kaiser Permanente Phase 4 2015-06-01 This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older, with VIEKIRA PAK (ombitasvir, paritaprevir/r, dasubuvir), with or without ribavirin.
NCT02745535 Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Subjects With Previous DAA Experience Recruiting Gilead Sciences Phase 2 2016-03-01 This study will evaluate the safety, tolerability, and efficacy of sofosbuvir/velpatasvir/GS-9857 (SOF/VEL/GS-9857) in adults with chronic hepatitis C infection who have failed to eradicate hepatitis C despite previous combination directly acting antiviral therapy.
NCT02745535 Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Subjects With Previous DAA Experience Recruiting Unity Health Care, Inc. Phase 2 2016-03-01 This study will evaluate the safety, tolerability, and efficacy of sofosbuvir/velpatasvir/GS-9857 (SOF/VEL/GS-9857) in adults with chronic hepatitis C infection who have failed to eradicate hepatitis C despite previous combination directly acting antiviral therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for VIEKIRA XR

Condition Name

Condition Name for VIEKIRA XR
Intervention Trials
Chronic Hepatitis C 3
Hepatitis C, Chronic 1
Chronic Kidney Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for VIEKIRA XR
Intervention Trials
Hepatitis C, Chronic 4
Hepatitis C 4
Hepatitis, Chronic 3
Hepatitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for VIEKIRA XR

Trials by Country

Trials by Country for VIEKIRA XR
Location Trials
United States 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for VIEKIRA XR
Location Trials
Massachusetts 2
California 2
Maryland 2
District of Columbia 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for VIEKIRA XR

Clinical Trial Phase

Clinical Trial Phase for VIEKIRA XR
Clinical Trial Phase Trials
Phase 4 2
Phase 2 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for VIEKIRA XR
Clinical Trial Phase Trials
Recruiting 2
Not yet recruiting 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for VIEKIRA XR

Sponsor Name

Sponsor Name for VIEKIRA XR
Sponsor Trials
AbbVie 3
Unity Health Care, Inc. 1
Gilead Sciences 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for VIEKIRA XR
Sponsor Trials
Industry 6
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Mallinckrodt
Merck
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.